ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2216

Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2352

High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease

(2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

9:00AM-11:00AM: Abstract Number: 1716

High-Throughput Semi-Automated Micro-CT Analysis Identifies the Cuboid Bone as a Sex-Dependent Biomarker of Inflammatory-Erosive Arthritis in TNF-Tg Mice

(1713–1733) RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1823

Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia

(1796–1826) Epidemiology & Public Health Poster III

9:00AM-11:00AM: Abstract Number: 1936

Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 2128

Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1744

Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1858

How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 2226

How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 1994

How Is Paracetamol Prescribed in Low Back Pain and Osteoarthritis in France? Paracetamol Prescription Patterns in the Real-World General Practice

(1977–1995) Osteoarthritis – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1998

How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1724

Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects

(1713–1733) RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1852

Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 2343

Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 2327

Hydroxychloroquine Improves Low Complement Levels

(2326–2351) SLE – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].